KALA BIO, Inc. — fact timeline

KALA BIO, Inc. issued common stock.

“KALA BIO , Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares.”

KALA BIO, Inc.: Amended the restated certificate of incorporation to effect a 1-for-50 reverse stock split of common stock, effective May 8, 2026 (effective 2026-05-08).

“On May 7, 2026, KALA BIO, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on May 8, 2026 (the “ Reverse Stock Split ”).”

KALA BIO, Inc. issued 5,000,000 shares of the Company’s common stock of common stock to 2624465 Ontario Inc. o/a Younet AI for up to $530,000 in cash, of which $80,000 paid on Effective Date, and up to $450,000 additional.

“by the Company. In consideration of the services to be performed by Younet under the Agreement, the Company has agreed to pay to Younet for the Initial Term a cash fee of up to $530,000 consisting of (i) $80,000 in cash, which was paid by the Company on the Effective Date, and (ii) in the event the Company delivers to Younet a written notice electing to engage”

KALA BIO, Inc. entered into Agreement with 2624465 Ontario Inc. o/a Younet AI (effective 2026-03-03).

“On March 3, 2026 (the “Effective Date”), KALA BIO, Inc. (the “Company”) and 2624465 Ontario Inc. o/a Younet AI, an Ontario corporation (“Younet”) entered into a Platform Development and Exclusive License Agreement (the “Agreement”)”

KALA BIO, Inc. issued 2,100,000 shares of Series AAA Preferred Stock of preferred stock to Series AAA Investors for $2.00 per share, for aggregate gross proceeds of $4.2 million.

“an aggregate of 2,100,000 shares of Series AAA Preferred Stock at a price per share of Series AAA Preferred Stock equal to $2.00, for aggregate gross proceeds of $4.2 million.”

KALA BIO, Inc.: Stockholders approved an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 1,500,000,000, effective January 30, 2026 (effective 2026-01-30).

“Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As described below under Item 5.07 of this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (as amended, the “ Restated Certificate of Incorporation ”), to increase the number of authorized shares of the Common Stock 1,500,000,000 shares. The increase in the number of authorized shares of Common Stock was affected pursuant to a Certificate of Amendment to the Restated Certificate of Incorporation (the “ Certificate of Amendment ”) filed with the Secretary of State of the State of Delaware on January 30, 2026, and was effective as of such date.”

KALA BIO, Inc. entered into Purchase Agreement with Series AAA Investors valued at aggregate gross proceeds of $4.2 million (effective 2026-01-30).

“On January 30, 2026, the Company entered into that certain Securities Purchase Agreement (the “ Purchase Agreement ”) with each of the Series AAA Investors”

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 20, 2026, KALA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“ Nasdaq ”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or unti”

KALA BIO, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-01-08).

“On January 8, 2026, KALA BIO, Inc. (the “ Company ”), entered into an At The Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”)”

KALA BIO, Inc. issued 1,100,000 shares of common stock to Delaware IR LLC for settlement of the outstanding $600,000 amount owed under the consulting agreement.

“agreement with Delaware IR LLC (“Delaware IR”). Under the consulting agreement, Delaware IR agreed to provide marketing and advertising services for a six-month term for $600,000. Under the settlement agreement, the Company agreed to issue 1,100,000 shares of Common Stock to settle the outstanding $600,000 amount owed under the consulting agreement, with”

KALA BIO, Inc. entered into Delaware IR Settlement with Delaware IR LLC valued at Issued 1,100,000 shares of common stock to settle $600,000 owed (effective 2025-12-30).

“Under the settlement agreement, the Company agreed to issue 1,100,000 shares of Common Stock to settle the outstanding $600,000 amount owed under the consulting agreement, with a make-whole mechanic tied to ultimate net sale proceeds from the future sales of the 1,100,000 shares of Common Stock (the “Delaware IR Settlement”).”

KALA BIO, Inc. entered into Delaware IR Consulting Agreement with Delaware IR LLC valued at Marketing and advertising services for six months for $600,000 (effective 2025-12-30).

“On December 30, 2025, the Company also entered into a consulting agreement and a settlement agreement with Delaware IR LLC (“Delaware IR”). Under the consulting agreement, Delaware IR agreed to provide marketing and advertising services for a six-month term for $600,000.”

KALA BIO, Inc. entered into LifeSci Settlement with LifeSci Capital LLC valued at Issued 2,200,000 shares of common stock (effective 2025-12-30).

“On December 30, 2025, the Company also entered into a settlement agreement with LifeSci Capital LLC (“LifeSci”) under which the Company agreed to issue 2,200,000 shares of Common Stock to settle certain payment obligations for financial advisory services (the “LifeSci Settlement”).”

KALA BIO, Inc. entered into Baker Voting Agreement with Baker Bros. Advisors LP valued at Granted irrevocable proxy for six months (effective 2025-12-30).

“In connection with the Baker Settlement, the Company and Baker Bros. also entered into a voting agreement (the “Baker Voting Agreement”) under which Baker Bros. granted an irrevocable proxy in favor of the Company to vote the settlement shares and other specified shares in line with the Company’s board of director’s recommendations for a period of six months.”

KALA BIO, Inc. entered into Baker Settlement with Baker Bros. Advisors LP valued at Issued 900,000 shares of common stock (effective 2025-12-30).

“On December 30, 2025, KALA BIO, Inc. (the “Company”) entered into a settlement agreement with Baker Bros. Advisors LP (“Baker Bros.”) under which the Company agreed to issue 900,000 shares of its common stock, par value $0.001 per share (“Common Stock”) to resolve certain claims relating to participation rights under prior financing arrangements (the “Baker Settlement”).”

KALA BIO, Inc. engaged HTL International, LLC as its auditor.

“On December 19, 2025, the Audit Committee approved the engagement of HTL International, LLC (“HTL”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

KALA BIO, Inc. dismissed Deloitte & Touche LLP as its auditor.

“the audit committee of the Company’s Board of Directors approved the dismissal of Deloitte & Touche LLP as the Company’s independent registered public accounting firm.”

KALA BIO, Inc. dismissed Deloitte & Touche LLP as its auditor.

“(the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective as of December 15, 2025.”

KALA BIO, Inc. entered into Securities Purchase Agreement with the Investor valued at up to $6.0 million (effective 2025-11-23).

“On November 23, 2025 (the “SPA Effective Date”), the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the Investor, pursuant to which the Company agreed to issue and sell, in a private placement, shares”

KALA BIO, Inc. issued 2,100,000 Series AAA Preferred Shares of preferred stock to the Investor for $2.00 per Series AAA Preferred Share.

“Company has also agreed to issue and sell to the Investor at a second closing of the Private Placement (the “Second Closing”), 2,100,000 Series AAA Preferred Shares, at a price per Series AAA Preferred Share equal to $2.00, for aggregate gross proceeds of $4.2 million”

KALA BIO, Inc. issued 900,000 Series AA Preferred Shares of preferred stock to the Investor for $2.00 per Series AA Preferred Share.

“Company has agreed to issue and sell to the Investor at a first closing of the Private Placement to be held immediately following the execution of the Securities Purchase Agreement (the “First Closing”), 900,000 Series AA Preferred Shares, at a price per Series AA Preferred Share equal to $2.00, for aggregate gross proceeds of $1.8 million. The First Closing occurred on November 24, 2025”

KALA BIO, Inc.: Filed Certificate of Designations for Series AA Convertible Non-Redeemable Preferred Stock establishing rights, preferences, and privileges (effective 2025-11-24).

“On November 24, 2025 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series AA Convertible Non-Redeemable Preferred Stock (the “Series AA Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series AA Preferred Stock.”

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“November 10, 2025, KALA BIO, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”) for continued listing on The Nasdaq Capital Market, as the market value of the Company’s listed securities was less than $35 million for the previous 30 consecutive business days. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative sta”

KALA BIO, Inc. issued convertible note to individual investor for aggregate amount of up to $375,000.

“On November 9, 2025 (the “Execution Date”), KALA Bio, Inc. (the “Company”) entered into a Convertible Loan Agreement (the “Loan Agreement”) with an individual investor (the “Lender”), pursuant to which the Lender agreed to provide the Company a convertible loan in the aggregate amount of up to $375,000”

KALA BIO, Inc. announced a restructuring affecting Company's remaining assets (terminated all remaining employees not deemed necessary by Oxford to execute a foreclosure of the Company’s assets).

“On October 19, 2025, the Board terminated all remaining employees not deemed necessary by Oxford to execute a foreclosure of the Company’s assets (the “Reduction”).”

KALA BIO, Inc. announced a restructuring with charges of approximately $0.4 million affecting KPI-012 and its mesenchymal stem cell secretome platform (approximately 19 employees, or approximately 51%).

“generally accepted accounting principles as a result of the Reduction. Subsequent to the Original Report, the Company determined that it expects to incur costs of approximately $0.4 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. The costs related to the Reduction are expected to be substantially incurred in”

KALA BIO, Inc. faced acceleration on loan of $29.1 million with Oxford Finance LLC at Default Rate.

“the Event of Default. The total amount of the Company’s obligations under the Loan Agreement as of the date hereof that have been accelerated and declared payable by Oxford is $29.1 million plus any additional interest due upon final payment and any expenses that become payable by the Company under the Loan Agreement. A description of the Loan Agreement is contained”

KALA BIO, Inc. announced a restructuring affecting the Company's workforce (approximately 19 employees, or approximately 51%).

“On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options. In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).”

Todd Bazemore was appointed as interim Chief Executive Officer and principal executive officer at KALA BIO, Inc..

“On February 11, 2025, the Board appointed Todd Bazemore as the interim Chief Executive Officer and principal executive officer of the Company, effective immediately.”

Mark Iwicki resigned as Chief Executive Officer at KALA BIO, Inc..

“On February 11, 2025, Mark Iwicki notified KALA BIO, Inc. (the “Company”) of his decision to resign as the Chief Executive Officer of the Company, effective immediately.”

KALA BIO, Inc.: Filed Certificate of Designations establishing Series I Convertible Non-Redeemable Preferred Stock (effective 2024-12-30).

“On December 30, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series I Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series I Preferred Stock.”

Mark S. Blumenkranz resigned as Director at KALA BIO, Inc..

“On September 23, 2024, Mark S. Blumenkranz, M.D. notified KALA BIO, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.”

KALA BIO, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update.”

KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2023.

“On March 29, 2024, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

KALA BIO, Inc.: Filed Certificate of Designations for Series G Convertible Non-Redeemable Preferred Stock (effective 2024-03-25).

“On March 25, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series G Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series G Preferred Stock.”

KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors named therein valued at aggregate gross proceeds of approximately $8.6 million (effective 2024-03-25).

“On March 25, 2024, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series G Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series G Preferred Stock”), for aggregate gross proceeds of approximately $8.6 million (the “Private Placement”).”

KALA BIO, Inc.: Filed Certificate of Designations for Series F Convertible Non-Redeemable Preferred Stock, establishing rights, preferences, and privileges (effective 2023-12-21).

“On December 21, 2023 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series F Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series F Preferred Stock.”

KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $2.0 million (effective 2023-12-21).

“On December 21, 2023, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series F Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series F Preferred Stock”), for aggregate gross proceeds of approximately $2.0 million (the “Private Placement”).”

KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2023.

“On November 13, 2023, KALA BIO, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

KALA BIO, Inc.: Amended and restated bylaws solely to reflect name change to KALA BIO, Inc (effective 2023-08-02).

“the Board also approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws solely to reflect the Name Change (as amended and restated, the “Third Amended and Restated By-Laws”) effective as of August 2, 2023”

KALA BIO, Inc.: Amended certificate of incorporation to change company name from Kala Pharmaceuticals, Inc. to KALA BIO, Inc (effective 2023-08-02).

“Effective as of 4:00 p.m., Eastern Time on August 2, 2023, Kala Pharmaceuticals, Inc. (the “Company”) amended its Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a change of the Company’s name from “Kala Pharmaceuticals, Inc.” to “KALA BIO, Inc.””

KALA BIO, Inc. shareholders rejected Amendment to Restated Certificate of Incorporation to change company name to Kala Bio, Inc..

“were as follows: ​ Votes For Votes Against Votes Abstaining Broker Non- Votes 1,151,465 11,194 2,924 0”

KALA BIO, Inc. shareholders approved Approval of Amended and Restated 2017 Stock Option and Incentive Plan.

“were as follows: ​ Votes For Votes Against Votes Abstaining Broker Non- Votes 495,640 71,992 3,519 594,432”

KALA BIO, Inc. shareholders approved Non-binding advisory vote on frequency of future say-on-pay votes.

“were as follows: ​ Every One Year Every Two Years Every Three Years Votes Abstaining Broker Non- Votes 546,761 4,425 17,435 2,530 594,432”

KALA BIO, Inc. shareholders approved Non-binding advisory vote on compensation paid to named executive officers.

“2. The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results”

KALA BIO, Inc. shareholders approved Election of C. Daniel Myers and Howard B. Rosen as Class III directors.

“The results of the stockholders’ vote with respect to the election of such Class III directors were as follows: ​ Votes For Votes Withheld Broker Non- Votes C. Daniel Myers 544,974 26,177 594,432 Howard B. Rosen 550,334 20,817 594,432”

KALA BIO, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 9, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a general business update.”

KALA BIO, Inc. shareholders approved Adjournment of Special Meeting to permit further solicitation if necessary at the 2023-04-24 meeting.

“3. The Company’s stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal and the Auditor Ratification Proposal. The results of the stockholders’ vote with respect to such adjournment proposal were as follows: ​ Votes For Votes Against Votes Abstaining Broker Non- Votes 873,292 ​ 94,743 ​ 5,183 ​ 0”

KALA BIO, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-04-24 meeting.

“2. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (the “Auditor Ratification Proposal”). The results of the stockholders’ vote with respect to such ratification were as follows: ​ Votes For Votes Against Votes Abstaining Broker Non- Votes 937,505 ​ 23,974 ​ 11,739 ​ 0”

KALA BIO, Inc. shareholders approved One-time exchange of stock options for newly issued restricted stock units (Option Exchange Proposal) at the 2023-04-24 meeting.

“1. The Company’s stockholders approved the one-time exchange of stock options issued under the Company’s 2009 Employee, Director and Consultant Equity Incentive Plan, the Company’s 2017 Equity Incentive Plan, and inducement awards granted to certain newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4) that are held by executive officers, other employees, and non-employee directors of the Company for newly issued restricted stock units (the “Option Exchange Proposal”). The results of the stockholders’ vote with respect to the Option Exchange Proposal were as follows: ​ Votes For Votes Against Votes Abstaining Broker Non- Votes 385,429 ​ 57,585 ​ 4,580 ​ 525,624”